Covid vaccines are back in the headlines after recent admission by AstraZeneca, the pharmaceutical company, that its AstraZeneca-Oxford vaccine 'can, in very rare cases, cause Thrombosis Thrombocytopenia Syndrome (TTS)', which is one of those situations where there can be clots formed in the blood vessels.

最近，制药公司阿斯利康（AstraZeneca）承认，其阿斯利康牛津疫苗“在极少数情况下会导致血栓形成血小板减少综合征（TTS）”，这是血管中可能形成凝块的情况之一，因此新型冠状病毒疫苗再次成为头条新闻。

Despite these rare occurrences, the pharmaceutical company maintains that extensive clinical trial data and real-world evidence consistently support the vaccine's safety and efficacy. In India, the Oxford- AstraZeneca vaccine was made under licence as Covishield. According to news agency ANI, the Serum Institute of India produced a COVID-19 vaccine named Covishield but not using mRNA platform.

尽管发生了这些罕见的事件，但该制药公司坚持认为，广泛的临床试验数据和现实世界的证据始终支持疫苗的安全性和有效性。在印度，牛津-阿斯利康疫苗是在Covishield许可下生产的。据ANI通讯社报道，印度血清研究所生产了一种名为Covishield的新型冠状病毒肺炎疫苗，但没有使用mRNA平台。

It has been prepared using the viral vector platform. In the vaccine, a chimpanzee adenovirus - ChAdOx1 - has been modified to enable it to carry the COVID-19 spike protein into the cells of humans.What WHO said on TTS risk from covid vaccines In 2023, the World Health Organization (WHO) reported the emergence of Thrombotic Thrombocytopenia Syndrome (TTS) as a rare adverse event associated with COVID-19 non-replicant adenovirus vector-based vaccines, epecifically, individuals vaccinated with AstraZeneca's ChAdOx-1 vaccine and Johnson & Johnson's Janssen COVID-19 Ad26.COV2-S vaccine.'Knowledge about TTS following vaccination with a COVID-19 adenovirus vector-based vaccine is rapidly evolving.

它是使用病毒载体平台制备的。在疫苗中，黑猩猩腺病毒ChAdOx1已被修饰，使其能够携带COVID-19尖峰蛋白进入人类细胞。世卫组织关于新型冠状病毒疫苗TTS风险的说法2023年，世界卫生组织（WHO）报告称，血栓性血小板减少综合征（TTS）的出现是一种罕见的不良事件，与新型冠状病毒19非复制腺病毒载体疫苗有关，特别是接种阿斯利康（AstraZeneca）的ChAdOx-1疫苗和强生（Johnson＆Johnson）的Janssen covid-19 Ad26.COV2-s疫苗的个体接种基于COVID-19腺病毒载体的疫苗后，有关TTS的知识正在迅速发展。

WHO will continue to monitor the situation closely for any changes that may affect this interim guidance and will update the guidance as needed,' WHO said in its April 2023 report. In patients exhibiting platelet-activating anti-PF4 (PF4) antibodies, this condition has been identified as vaccine-induced immune thrombotic thrombocytopenia (VITT).

世卫组织在2023年4月的报告中说，世卫组织将继续密切监测局势，以了解可能影响这一临时指导意见的任何变化，并将根据需要更新指导意见。在表现出血小板活化抗PF4（PF4）抗体的患者中，这种情况已被确定为疫苗诱导的免疫性血栓性血小板减少症（VITT）。

Some individuals may experience delayed-onset .

有些人可能会延迟发作。